Shortage of canine heartworm treatment to continue

12/4/2013 | Plain Dealer (Cleveland), The

Immiticide, the only FDA-approved treatment for canine heartworm disease, has been in short supply since 2009 regulatory changes complicated importation of an arsenic-based ingredient. Production problems at the Ohio plant exacerbated the issue, and now the plant is poised to close. For now, veterinarians can obtain the drug on a case-by-case basis, and FDA Center for Veterinary Medicine officials said this week that limited imports will continue. In the meantime, veterinarian Dave Koncal, president-elect of the Ohio Veterinary Medical Association, said the situation serves as an important reminder that owners should be vigilant about keeping dogs on heartworm prevention medication.

View Full Article in:

Plain Dealer (Cleveland), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD